The purpose of this study was to assess the management of both hypertension and micro/macroalbuminuria in a cohort of type II diabetic patients. In the first 6 months of the year 2000, 5815 diabetic patients were identified through prescriptions for antidiabetic drugs in our sanitary district (191 568 inhabitants). In all, 65% (3810) of these type II diabetic patients were also given prescriptions for antihypertensive drugs. A total of 400 diabetic patients were randomly selected and 171 entered the study (gender: 94/77 M/F; age: 66.6 7 8 years; diabetes duration: 12 7 9 years): 100 patients (group DT) were treated with antihypertensive drugs and 71 (group DU) were untreated. Blood pressure, urine albumin-to-creatinine ratio (ACR), and glycated haemoglobin were measured in the two groups. A total of 80% (57/71) of DU patients were hypertensive (BPX130/ 85 mmHg). Specifically, 24.4% had diastolic hypertension (BPX85 mmHg) and 79% systolic hypertension (BPX130 mmHg). Only 63% (100/157) of the hypertensive patients were treated with antihypertensive drugs (two drugs/patient on average, range 1-5). In addition, only 13% of the DT patients were adequately controlled (BPo130/85 mmHg), while the others had above target blood pressure levels (14%: 130-139/85-89 mmHg; 40%: 140-159/90-95 mmHg, and 33%X160/ 95 mmHg). Angiotensin converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) were included in the antihypertensive medical regimen in 70% of the DT patients (ACE-I: 62%; ARB: 8%; diuretics: 39%; dihydropyridine calcium antagonists: 38%; a-blockers: 20%, b-blockers: 17%; clonidin: 8%; nondihydropyridine calcium antagonists: 5%). Only 33% of type II diabetic patients underwent a screening for microalbuminuria as assessed on clinical records. The same percentage of micro-and macroalbuminuric patients (13.5%) was observed in the DT group, whereas 25% micro vs 3% macro were found in the DU group. In all, 73% of microalbuminuric patients were not on ACE-I/ARB. Hypertensive type II diabetic patients were often left untreated and only a minority of those treated were optimally controlled. The importance of an elevated systolic pressure is underestimated and the number of antihypertensive drugs prescribed insufficient. Screening and treatment of albuminuria are inadequate.
Introduction
The prevalence of type II diabetes is increasing worldwide. 1 Diabetes is commonly associated with hypertension, and the coexistence of elevated blood pressure further increases the risk of cardiovascular and renal disease in diabetic patients. 2 The United Kingdom Prospective Diabetes Study (UKPDS) has showed that tight blood pressure control (median, 144/82 vs 154/87 mmHg) reduces the risk of death, stroke and microvascular disease. 3 The target blood pressure level in patients with diabetes is o130/80-85 mmHg. [4] [5] [6] [7] [8] Diabetic nephropathy develops in approximately 40% of patients with type II diabetes, and it is the leading cause of end-stage renal failure in the Western world. 9, 10 Microalbuminuria is a risk factor for the development of overt diabetic nephropathy. 10, 11 Blockade of the renin-angiotensin system slows the progression of nephropathy both in patients with microalbuminuria and macroalbuminuria. [12] [13] [14] [15] [16] [17] The purpose of this study was to assess the management of both hypertension and micro/ macroalbuminuria in a cohort of type II diabetic patients attending general practises.
Subjects and methods

Patient selection
The study was performed in a major health-care district (191 568 inhabitants) in Turin, Italy. A total of 5815 diabetic patients (M/F ¼ 0.85, mean age 67 7 12 years), 3810 (65%, M/F ¼ 0.73, age 69 7 10 years) treated with antihypertensive drugs and 2005 (35%, M/F ¼ 1.15, age 63 7 14 years) untreated, were identified through prescriptions for antidiabetic and antihypertensive drugs (Anatomical Therapeutic Chemical codes A10A-A10B and CO2-CO3-CO7-CO8-CO9, respectively) received by the Pharmaceutical Service between 1 January 2000 and 30 June 2000. In all, 200 patients for each group (age 418 years) were randomly selected and invited (by letter or phone call) to participate in the study. Seven patients were deceased, three were not found, seven were willing but unable to participate, and 207 refused to enter the study. Three patients with type I diabetes and two patients, who underwent renal transplant, were excluded.
A total of 100 type II diabetic patients treated with antihypertensive drugs (DT) and 71 untreated (DU) were included in the study. The percentage of patients randomly selected, who did not enter the study, was significantly higher in the DU than in the DT group (50 vs 35.5%, P ¼ 0.0034). Diagnosis of diabetes was confirmed using patient's records ( Figure 1 ).
Clinical data collection
Patients were asked to attend our outpatient clinic and to give their informed consent. The following information were gathered: education, smoke habits, duration of both diabetes and hypertension, previous cardiovascular events (coronary artery disease, stroke and peripheral vascular disease), current drug therapy (each drug was considered separately when fixed-dose combination drugs were used), overall compliance with therapy (selfreported and scored as good, intermediate, or poor), systolic and diastolic blood pressure levels reported in the patient's records, previous assessment of diabetic retinal and renal complications by fundoscopy, and screening for microalbuminuria. Height and weight were measured, and body mass index (BMI) calculated (kg/m 2 ).
Blood pressure measurement
Blood pressure was measured in the seated position after a 5 min rest with a Omron HEM 705 CP device. The results of three consecutive readings were averaged. Thereafter, blood pressure was measured after 2 min of standing. In patients with atrial fibrillation, a standard sphygmomanometer was used. Hypertension was defined as a blood pressure X130/85 mmHg.
Biochemical measurements
A venous blood sample for the determination of glycated haemoglobin and a fasting spot morning urine sample for standard analysis and determination of albumine-to-creatinine ratio (ACR) were collected. Glycated haemoglobin was measured by HPLC (Variant II, Bio-Rad, Munchen, Germany, normal range 3.9-6.1%), urinary albumin by immunoturbidimetry (Tina-quant Roche/Hitachi, Basel, Switzerland), and urinary creatinine by the kinetic Jaffè method (Roche/Hitachi, Basel, Switzerland). The ACR ratio was expressed in mg/g. Cutoff values for microalbuminuria were gender-and ageadjusted according to Houlihan et al. 18 Macroalbuminuria was defined as ACRX300 mg/g. Three cases were positive for urinary nitrites and they were excluded from the analysis. ACR values were available in 96 out of 100 DT patients and in 67 out of 71 DU patients.
Statistical analysis
Statistical analyses were performed using SPSS version 11.0 (SPSS, Chicago, IL, USA). Data are expressed as mean 7 s.d. Median (range) were used for not normally distributed variables.
Data were analysed using Student's t-test, MannWhitney U test, w 2 test, and ANOVA as appropriate. Univariate odds ratios were calculated with the Mantel-Haenszel test, and multivariate analysis with logistic regression. Table 1 shows patient demographic and clinical data. In univariate analyses, antihypertensive treatment was significantly correlated with: previous coronary events (OR 3.9; 95% CI 1. 
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Blood pressure
In all, 57 out of 71 DU patients (80.3%). were hypertensive. A similar percentage (81.2%) was obtained when we used the latest blood pressure value recorded in the patients' records. Table 2 shows blood pressure and heart rate values. In Tables 3 and 4 , patients are divided according to both measured and reported systolic and diastolic blood pressure levels.
A total of 100 out of 157 hypertensive patients (63.7%) were treated with antihypertensive medications. Among them, 13 patients (13%) had BP values o130/85 mmHg, 14 patients (14%) between 130-139/85-89 mmHg, 40 patients (40%) between 140-159/90-95 mmHg, and 33 patients (33%) X160/ 95 mmHg.
A total of 38 patients (38%) received one antihypertensive drug, 35 patients (35%) two, 19 patients (19%) three, five patients (5%) four, and one patient (1%) five. In two patients, the number and type of antihypertensive drug used were unknown. On average, patients were receiving two drugs each. Among patients on monotherapy, drugs more frequently used were angiotensin-converting enzyme inhibitors (ACE-I, n ¼ 13; 36.1%) and dihydropyridine calcium antagonists (n ¼ 13; 36.1%), followed by a-blockers (n ¼ 4; 11.1%), diuretics (n ¼ 4; 11.1%), nondihydropyridine calcium antagonists (n ¼ 1; 2.8%), and angiotensin receptor blockers (ARB, n ¼ 1; 2.8%).
Among patients on two antihypertensive drugs, the combination more frequently used was ACE-I plus diuretics (n ¼ 11; 31%), followed by both ACE-I plus a-blockers (n ¼ 8; 23%) and ACE-I plus dihydropyridine calcium antagonists (n ¼ 7; 20%).
Patients treated with Xthree drugs used various combinations, which included a diuretic in 78% of Treatment of hypertension and albuminuria in type II diabetes R Boero et al the cases. A diuretic was used in 40% of the patients treated with a combination of two antihypertensive drugs. As a whole, ACE-I was used in 62% of the patients treated with antihypertensive drugs, diuretics in 39%, dihydropyridine calcium antagonists in 38%, a-blockers in 20%, b-blockers in 17%, ARBs in 8%, clonidin in 8%, and nondihydropyridine calcium antagonists in 5%. Table 5 shows age, BMI, glycated haemoglobin and number of antihypertensive medications prescribed in the DT patients according to blood pressure values.
Urinary albumin excretion
Patient's charts showed that 48 patients out of 144 (33.3%) were screened at least once for increased albumin excretion rate during the year 2000.
Microalbuminuria and macroalbuminuria were present in 13 and 13 DT patients (13.5% and 13.5%) respectively. Among DU patients, 17 (25%) were microalbuminuric and two (3%) macroalbuminurics and this difference was statistically significant (P ¼ 0.036). In all, 73% (22/30) of the microalbuminuric patients and 33% (5/15) of the macroalbuminurics were not taking ACE-I or ARB. In micro/macroalbuminuric patients, treatment with ACE-I/ARB was significantly correlated with duration of hypertension 4 5 years (OR 32, 95% CI 3-335), education X8 years (OR 6.1, 95% CI 1.5-25.8), and macroalbuminuria (OR 4.7, 95% CI 1.3-17.1). In multivariate logistic regression, no variable persisted independently significantly associated with treatment with ACE-I or ARB.
Discussion
Our data show that arterial hypertension is not adequately treated and controlled in patients with type II diabetes resident in our area. These results are in agreement with previous reports on the management of hypertension in both diabetic and nondiabetic subjects. [19] [20] [21] [22] [23] [24] [25] [26] [27] In particular, systolic hypertension appears inadequately treated and controlled in our cohort despite the fact that the UKPDS study 28 has demonstrated that the incidence of clinical complications and deaths related to diabetes is significantly associated with systolic blood pressure, without evidence of a threshold. Major determinants in the probability of being treated with antihypertensive therapy for a type II diabetic subject with hypertension are the patient compliance, previous fundoscopy, and previous coronary/cerebrovascular events. This suggests that antihypertensive therapy is started when there is already clinical evidence of vascular damage. The number of antihypertensive medications prescribed to our patients (two drugs/patient on average) was much lower than the 3.2 drugs that were required to achieve blood pressure target levels in intervention trials, including type II diabetic patients. 6 Only 39% of the DT patients were taking diuretics, and 60% of the patients on two antihypertensive drugs were not on diuretics. In diabetic patients, diuretics have been recommended as the second choice drug by a consensus document from the National Kidney Fundation Hypertension and Diabetes Executive Committees Working Group, 6 as well as by a recent guideline based on current evidence. 29 However, when our study was Treatment of hypertension and albuminuria in type II diabetes R Boero et al carried out, the Italian guidelines suggested the use of diuretics as a third choice drug. 7 Accordingly, the percentage of patients in our study, who were not treated with diuretics, dropped to 22% among subjects receiving three or more antihypertensive drugs.
The number of antihypertensive medications prescribed increased along with blood pressure levels, suggesting poor responsiveness to treatment. Advanced age, poor metabolic control, and overweight emerged as possible explanations for poor response to antihypertensive therapy.
Both ACE-I and ARB are currently recommended in type II diabetic patients with microalbuminuria to prevent progression to overt nephropathy 13, 14, 17 and in patients with macroalbuminuria to slow renal function decline. 12, 15, 16 Our data show that these goals were far from being achieved: 73% of the patients with microalbuminuria and 33% of those with macroalbuminuria were treated neither with ACE-I nor with ARB. A similar percentage (60%) of microalbuminuric type II diabetic patients nontreated with ACE-I has been previously reported in the study by Hueston et al. 30 In micro/macroalbuminuric patients significant predictors for treatment with ACE-I/ARB were duration of hypertension, higher education, and presence of macroproteinuria. The observation that most patients (66.7%) were not systematically screened for microalbuminuria, but only for macroalbuminuria may explain why macroalbuminuric patients are more likely to be identified and to receive adequate ACE-I/ARB treatment.
This study has several potential limits. Firstly, we studied only type II diabetic patients treated with antidiabetic drug, and no information is available on diet-treated patients. Furthermore, the percentage of patients, who were randomised but did not enter the study, was significantly higher in the DU group than in the DT group, and this may represent a potential selection bias. Blood pressure was measured only in one occasion and high values were not rechecked. However, this is unlikely to affect our conclusions as results were similar when recorded blood pressure levels were used in the analysis. Albuminuria was measured in a single spot urine sample, but rather conservative cutoff limits for the definition of microalbuminuria with gender-and age-adjustments were used. Finally, the number of patients taking antihypertensive drug was too small to attempt to infer conclusions about the population as a whole.
In conclusion, our study shows that hypertension and micro/macroalbuminuria are not adequately managed in patients with type II diabetes in our sanitary district. To reduce the risk of cardiovascular and renal complications in these patients, we suggest a prompt start of antihypertensive therapy aiming at the lowest obtainable systolic blood pressure level. This can be achieved by using an appropriate number and type of medications. New fixed combinations, including two or even three antihypertensive agents, are often required. Blood pressure control should be paralleled by both improvement of metabolic control and reduction of body weight. Patients should be systematically screened and appropriately treated for microalbuminuria. Actions should be taken to overcome cultural and socio-economic barriers.
